Arca
Skip to content

Hepatic encephalopathy

Drug research and approvals for hepatic encephalopathy: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 22 studies of hepatic encephalopathy are recruiting on ClinicalTrials.gov, Health Canada has authorized 6 drug trials for it since 2013, and FDA has 1 approved and 3 open orphan designations naming it.

  • Recruiting worldwide: 22
  • Trials authorized in Canada: 6
  • FDA orphan approvals: 1
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 22 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

Newest first; search them all in Canada trials
Mar 7, 2022A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of rifaximin soluble solid dispersion (ssd) tablets for the…RIFAXIMINBausch HealthClosed
Dec 21, 2021A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of rifaximin soluble solid dispersion (ssd) tablets for the…RIFAXIMINBausch HealthOngoing
Dec 24, 2015A prospective open label single centre trial of rbx2660 (microbiota suspension) in the management of hepatic encephalopathy (he)RBX2660 (MICROBIOTA SUSPENSION)GOVERNORS OF THE UNIVERSITY OF ALBERTAOngoing
Apr 23, 2014A prospective, open label, single center trial of fecal microbiota transplantation (fmt) in the management of hepatic encephalopathyFECAL MICROBIOTA TRANSPLANTATIONGOVERNORS OF THE UNIVERSITY OF ALBERTAClosed
Dec 19, 2013Multicenter, randomized phase 2b study to evaluate the efficacy, safety and tolerability of ocr-002 (ornithine phenylacetate) in hospitalized patients with…OCR-002OCERA THERAPEUTICS INCOngoing
Aug 15, 2013"human biotherapy in the management of hepatic encephalopathy"HUMAN BIOTHERAPYGOVERNORS OF THE UNIVERSITY OF ALBERTAClosed

FDA Orphan Designations

Approved first, then open designations, newest first
Mar 24, 2010XifaxanReduction in the risk of overt hepatic encephalopathy (HE) recurrence in patients greater than or equal to 18 years of ageSalix Pharmaceuticals, Inc.Approved
Apr 7, 2010L-ornithine phenylacetateTreatment of hyperammonemia and resultant hepatic encephalopathy (HE) in patients with acute liver failure or acute on chronic liver disaseAmalive LimitedDesignated
Jun 3, 2005Sodium phenylacetate/sodium benzoate 10%/10% InjectionTreatment of grade III and IV hepatic encephalopathyUcyclyd Pharma, Inc.Designated
Mar 4, 2005Sodium aluminosilicateTreatment of chronic hepatic encephalopathyWesthaven Therapeutics CorporationDesignated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.